Press Release
« Back
Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
Mar 17, 2016
Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.
The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:
- Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Date/Time:Monday, April 18 ,8:00 a.m. -12:00 p.m. CDT
Location: Section 13
Abstract: CT023 - Title: Glycoprotein NMB (gpNMB)
overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma
Date/Time:Wednesday, April 20 ,8:00 a.m. -12:00 p.m. CDT
Location: Section 27
Abstract: 5032
- Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues
Date/Time:Monday, April 18 ,8:00 a.m. -12:00 p.m. CDT
Location: Section 21
Abstract: 1373
- Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy
Date/Time:Wednesday, April 20 ,8:00 a.m. -12:00 p.m. CDT
Location: Section 22
Abstract: 4866
The following
investigator-sponsored abstracts have been selected for poster presentations at AACR:
- Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy
Date/Time:Monday, April 18 ,8:00 a.m. -12:00 p.m. CDT
Location: Section 10
Abstract: LB-081
- Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer
Date/Time:Tuesday, April 19 ,1:00 p.m. -5:00 p.m. CDT
Location: Section 33
Abstract: 4209
- Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma
Date/Time:Sunday, April 17 ,1:00 p.m. -5:00 p.m. CDT
Location: Section 16
Abstract: 296
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact:Source:Sarah Cavanaugh Vice President of Investor Relations& Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 scavanaugh@celldex.comCharles Liles Manager of Investor Relations& Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 cliles@celldex.com Media Contact:Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com
News Provided by Acquire Media